You just read:

BeyondSpring Clinical Data for Lead Asset, Plinabulin, Accepted for Oral Presentation at IASLC's 2017 Targeted Therapies of the Treatment of Lung Cancer

News provided by

BeyondSpring Pharmaceuticals

23 Feb, 2017, 08:30 ET